PMID- 36455172 OWN - NLM STAT- MEDLINE DCOM- 20221205 LR - 20230510 IS - 2687-8941 (Electronic) IS - 2687-8941 (Linking) VI - 8 DP - 2022 Nov TI - Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study. PG - e2200205 LID - 10.1200/GO.22.00205 [doi] LID - e2200205 AB - PURPOSE: Atezolizumab plus bevacizumab treatment is a first-line therapy for unresectable hepatocellular carcinoma (HCC) worldwide. The efficacy, safety, and patient-reported outcomes (PROs) of HCC in Thailand have not yet been reported. This study aimed to evaluate the efficacy, safety, and PROs of atezolizumab plus bevacizumab. MATERIALS AND METHODS: From September 2020 to August 2021, 30 patients with unresectable HCC who met the inclusion criteria of atezolizumab plus bevacizumab as first-line treatment were enrolled. Analysis was assessed for progression-free survival, overall survival, adverse events (AEs), and quality of life (QoL). RESULTS: The median progression-free survival and overall survival periods were 6.7 and 10.2 months, respectively. The disease control rate was 63.3%. The frequent AEs were proteinuria, hypertension, and hepatitis. Serious AEs included gastrointestinal bleeding, but none of the patients died from serious AEs. The discontinuation rate was 23.3%, and the median number of treatment cycles was 10.5 cycles. In total, 23.3% of the patients continued treatment after 1 year of therapy. The global health status/QoL and physical function scores showed less deterioration at baseline than at 3 and 6 months (median scores = 76.7, 71.6, and 64.1 in QoL and 84.7, 79.6, and 79.0 in physical function, respectively). The HCC18 symptom score index data showed a slow progression of symptom scores from baseline to 3 and 6 months (12.7, 19.6, and 22.3, respectively). CONCLUSION: This study demonstrates that atezolizumab plus bevacizumab is effective and has a safety profile comparable with that of previous studies as first-line therapy for unresectable HCC in a real-world setting and in Thai populations. Data on PROs also demonstrate benefits in terms of patients' QoL and symptoms. FAU - Charonpongsuntorn, Chanchai AU - Charonpongsuntorn C AUID- ORCID: 0000-0001-8710-1020 AD - Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok, Thailand. FAU - Tanasanvimon, Suebpong AU - Tanasanvimon S AUID- ORCID: 0000-0002-3904-4719 AD - Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Korphaisarn, Krittiya AU - Korphaisarn K AUID- ORCID: 0000-0001-5739-0175 AD - Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital Mahidol University, Bangkok, Thailand. FAU - Payapwattanawong, Songwit AU - Payapwattanawong S AD - Oncology Unit, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Lak Hok, Thailand. FAU - Siripoon, Teerada AU - Siripoon T AD - Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Ramathibodi Hospital Mahidol University, Bangkok, Thailand. FAU - Pakvisal, Nussara AU - Pakvisal N AUID- ORCID: 0000-0001-8430-6151 AD - Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Juengsamarn, Jitlada AU - Juengsamarn J AD - Oncology Unit, Department of Medicine, Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand. FAU - Phaibulvatanapong, Ekkamol AU - Phaibulvatanapong E AUID- ORCID: 0000-0002-7524-2763 AD - Oncology Unit, Department of Medicine, Samutprakarn Hospital, Samut Prakan, Thailand. FAU - Chindaprasirt, Jarin AU - Chindaprasirt J AD - Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. FAU - Prasongsook, Naiyarat AU - Prasongsook N AUID- ORCID: 0000-0002-0634-2541 AD - Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Phramongkutklao University, Bangkok, Thailand. FAU - Udomdamrongkul, Kittipong AU - Udomdamrongkul K AD - Oncology Unit, Department of Medicine, Taksin Hospital, Bangkok, Thailand. FAU - Ngamphaiboon, Nuttapong AU - Ngamphaiboon N AUID- ORCID: 0000-0002-6535-6345 AD - Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Ramathibodi Hospital Mahidol University, Bangkok, Thailand. FAU - Sirachainan, Ekaphop AU - Sirachainan E AUID- ORCID: 0000-0003-2003-6249 AD - Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Ramathibodi Hospital Mahidol University, Bangkok, Thailand. LA - eng SI - TCTR/TCTR20200921003 PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PL - United States TA - JCO Glob Oncol JT - JCO global oncology JID - 101760170 RN - 52CMI0WC3Y (atezolizumab) RN - 2S9ZZM9Q9V (Bevacizumab) SB - IM MH - Humans MH - *Carcinoma, Hepatocellular/drug therapy MH - Quality of Life MH - Bevacizumab/adverse effects MH - Prospective Studies MH - Thailand/epidemiology MH - *Liver Neoplasms/drug therapy MH - Patient Reported Outcome Measures PMC - PMC10166432 COIS- The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Chanchai Charonpongsuntorn Research Funding: AstraZeneca Suebpong Tanasanvimon Honoraria: Eisai, MSD, Roche Canada, Bristol Myers Squibb/Celgene, Amgen, Lilly, Merck, Novartis, Ipsen, AstraZeneca Consulting or Advisory Role: Eisai, MSD, Bristol Myers Squibb/Celgene, Merck, Amgen Travel, Accommodations, Expenses: Fresinius Krabi Ekkamol Phaibulvatanapong Honoraria: Roche Consulting or Advisory Role: Roche Naiyarat Prasongsook Consulting or Advisory Role: AstraZeneca, Boehringer Ingelheim, Roche, Novartis, Bristol Myers Squibb/Celgene Travel, Accommodations, Expenses: AstraZeneca, Roche Nuttapong Ngamphaiboon Consulting or Advisory Role: MSD, Novartis, Amgen, Eisai, Merck Speakers' Bureau: Roche, Eisai, MSD, Novartis Research Funding: MSD (Inst), Pfizer (Inst), Roche (Inst), Exelixis (Inst), RAPT Therapeutics (Inst), BeiGene (Inst) Travel, Accommodations, Expenses: Roche Ekaphop Sirachainan Honoraria: MSD, Sanofi/Aventis, Merck, Amgen, Roche, Mundipharma, AstraZeneca, LF Asia, Diethelm Keller Group, Bristol Myers Squibb, Boehringer Ingelheim, Taiho Pharmaceutical, Dr Reddy's Laboratories, Zuellig Pharma, Meda Pharmaceuticals, Pfizer, Novo Nordisk, Novartis Consulting or Advisory Role: Roche, Taiho Oncology, MSD Oncology, Novartis, Bristol Myers Squibb/Celgene Travel, Accommodations, Expenses: MSD, AstraZeneca, Pfizer, Amgen, American Taiwan Biopharm, Taiho Pharmaceutical, Eisai No other potential conflicts of interest were reported. EDAT- 2022/12/02 06:00 MHDA- 2022/12/06 06:00 PMCR- 2022/12/01 CRDT- 2022/12/01 16:03 PHST- 2022/12/01 16:03 [entrez] PHST- 2022/12/02 06:00 [pubmed] PHST- 2022/12/06 06:00 [medline] PHST- 2022/12/01 00:00 [pmc-release] AID - GO.22.00205 [pii] AID - 10.1200/GO.22.00205 [doi] PST - ppublish SO - JCO Glob Oncol. 2022 Nov;8:e2200205. doi: 10.1200/GO.22.00205.